Navigation Links
Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information

NEW YORK, Jan. 4 /PRNewswire/ -- Berkery Noyes announced today that the firm represented The Thomson Corporation (NYSE: TOC; TSX: TOC) in the sale of CenterWatch ("CW") and New England Institutional Review Board ("NEIRB") to Jobson Medical Information, a portfolio company of The Wicks Group, LLC. Terms of the transaction were not disclosed.

Founded in 1994, CenterWatch is a trusted source and global leader in providing proprietary data and information about clinical trials to both professionals and patients. As a pioneer in publishing clinical trials information, CenterWatch was the first Internet site to publish detailed information about active clinical trials that could be assessed by patients and their advocates.

The NEIRB division provides FDA mandated services to pharmaceutical companies and Contract Research Organizations (CRO's). Founded in 1988, NEIRB was one of the first central institutional review boards established to meet the ethical review needs of a burgeoning drug development market.

"Both CW and NEIRB are winning franchises in the healthcare market and both have high caliber management and employees," said Tom O'Connor, the Berkery Noyes Managing Director who managed the transaction on behalf of The Thomson Corporation. "Within Jobson Medical Information portfolio these assets can grow and expand," added O'Connor.

Berkery Noyes acted as exclusive financial advisor to The Thomson Corporation on the sale of CenterWatch and NEIRB. Berkery Noyes has been involved with many of the most notable transactions in the healthcare, pharmaceutical tools and services, and medical marketing sectors involving both strategic and financial buyers and sellers.

About Berkery Noyes -- Berkery Noyes is one of the pre-eminent merger and acquisition firms serving the information industry, having completed more than 400 transactions since its inception. Among the most recent transactions completed by Berkery Noyes are the sale of HMP Communications to Alta Communications in partnership with Paul Mackler and Ken Fisher, the sale of Complete Healthcare Communications to MediMedia a portfolio company of Vestar Capital Partners, the divesture by The Thomson Corporation of American Health Consultants to Thompson Publishing Group; acquisition by Springer Science + Business Media of Current Medicine Group; acquisition by WebMd Corporation of Conceptis; acquisition by The Wicks Group of DesignWrite, Inc. and the acquisition by Veronis Suhler Stevenson of Facts On File.

Berkery Noyes' clients include private companies seeking a buyer, most of the major international information companies, and private equity firms who use the firm's expertise in locating, analyzing and negotiating with acquisition candidates and in managing divestitures. The firm operates with a staff of forty professionals serving the information and publishing industry. For more information, visit

About CenterWatch --

About New England Institutional Review Board --

SOURCE Berkery Noyes
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
4. Immunosyn Corporation Releases SF-1019 Study Results
5. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
6. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
7. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
8. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
9. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
10. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
11. Alfacell Corporation to Present at UBS Global Life Sciences Conference
Post Your Comments:
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), ... solutions, today announced that its MyDario product is expected to appear on ... for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The Dr. ... ...
(Date:9/22/2017)... Sept. 22, 2017  As the latest Obamacare repeal ... Bill Cassidy (R-LA) and Lindsey Graham ... the medical device industry is in an odd place. ... the 2.3% excise tax on medical device sales passed ... want covered patients, increased visits and hospital customers with ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/13/2017)... ... , ... “America On The Brink”: the Christian history of the United States ... creation of published author, William Nowers. Captain Nowers and his wife, Millie, have ... thirty years in the Navy. Following his career as a naval aviator and ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & ... by Moonlight to raise money for the American Heart Association Heart Walk. Teams of ... will work together to keep their treadmills moving for 5 hours. Treadmills will start ...
Breaking Medicine News(10 mins):